JPWO2021043955A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021043955A5
JPWO2021043955A5 JP2022514608A JP2022514608A JPWO2021043955A5 JP WO2021043955 A5 JPWO2021043955 A5 JP WO2021043955A5 JP 2022514608 A JP2022514608 A JP 2022514608A JP 2022514608 A JP2022514608 A JP 2022514608A JP WO2021043955 A5 JPWO2021043955 A5 JP WO2021043955A5
Authority
JP
Japan
Prior art keywords
antibody
human anti
medicament according
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022514608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547061A5 (https=
JP2022547061A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/074714 external-priority patent/WO2021043955A1/en
Publication of JP2022547061A publication Critical patent/JP2022547061A/ja
Publication of JPWO2021043955A5 publication Critical patent/JPWO2021043955A5/ja
Publication of JP2022547061A5 publication Critical patent/JP2022547061A5/ja
Priority to JP2025097923A priority Critical patent/JP2025148350A/ja
Pending legal-status Critical Current

Links

JP2022514608A 2019-09-05 2020-09-04 進展型小細胞肺癌（ｅｓ－ｓｃｌｃ）の治療のための組成物及び方法 Pending JP2022547061A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025097923A JP2025148350A (ja) 2019-09-05 2025-06-11 進展型小細胞肺癌（ｅｓ－ｓｃｌｃ）の治療のための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962896224P 2019-09-05 2019-09-05
US62/896,224 2019-09-05
PCT/EP2020/074714 WO2021043955A1 (en) 2019-09-05 2020-09-04 Compositions and methods for treating extensive stage small cell lung cancer (es-sclc)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025097923A Division JP2025148350A (ja) 2019-09-05 2025-06-11 進展型小細胞肺癌（ｅｓ－ｓｃｌｃ）の治療のための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2022547061A JP2022547061A (ja) 2022-11-10
JPWO2021043955A5 true JPWO2021043955A5 (https=) 2023-09-11
JP2022547061A5 JP2022547061A5 (https=) 2023-09-11

Family

ID=72521575

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022514608A Pending JP2022547061A (ja) 2019-09-05 2020-09-04 進展型小細胞肺癌（ｅｓ－ｓｃｌｃ）の治療のための組成物及び方法
JP2025097923A Pending JP2025148350A (ja) 2019-09-05 2025-06-11 進展型小細胞肺癌（ｅｓ－ｓｃｌｃ）の治療のための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025097923A Pending JP2025148350A (ja) 2019-09-05 2025-06-11 進展型小細胞肺癌（ｅｓ－ｓｃｌｃ）の治療のための組成物及び方法

Country Status (10)

Country Link
US (2) US12012453B2 (https=)
EP (1) EP4025249A1 (https=)
JP (2) JP2022547061A (https=)
KR (1) KR20220058601A (https=)
CN (1) CN114340673A (https=)
AU (2) AU2020342713A1 (https=)
CA (1) CA3151838A1 (https=)
IL (1) IL290834A (https=)
TW (1) TWI907357B (https=)
WO (1) WO2021043955A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119255817A (zh) * 2022-03-28 2025-01-03 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
TW202602492A (zh) * 2024-04-05 2026-01-16 瑞典商阿斯特捷利康公司 局限期小細胞肺癌之治療

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
EP3277318A1 (en) * 2015-04-01 2018-02-07 Medimmune Limited Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
ES2980794T3 (es) * 2015-09-15 2024-10-03 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor de CD19 y un inhibidor de BTK
AR108468A1 (es) * 2016-05-13 2018-08-22 Medimmune Llc POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS
SG10202110707UA (en) * 2017-03-30 2021-11-29 Merck Patent Gmbh Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
CN112585166A (zh) * 2018-06-23 2021-03-30 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂、铂剂和拓扑异构酶ii抑制剂治疗肺癌的方法

Similar Documents

Publication Publication Date Title
CN111065411A (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
US12295962B2 (en) Polymorphic compounds and uses thereof
WO2020187152A1 (zh) 治疗小细胞肺癌的联用药物组合物
CN113811298B (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
WO2020249018A1 (zh) 治疗驱动基因阳性肺癌的联用药物组合物
EP4512421A1 (en) Drug combination of anti-tim-3 antibody and anti-pd-1 antibody
TWI870592B (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
US20210353648A1 (en) Grapiprant unit dosage forms
CN111973747A (zh) 用于联合治疗卵巢癌的喹啉衍生物
JP2024539476A (ja) 医薬組成物およびその使用
JPWO2021043955A5 (https=)
CN114728003A (zh) 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合
JP2025531278A (ja) 医薬組成物およびその使用
JP7824627B2 (ja) 癌療法のためのイアダデムスタット（ｉａｄａｄｅｍｓｔａｔ）の組み合わせ物
TWI671072B (zh) 曲氟尿苷(trifluridine)/替匹拉希(tipiracil)鹽酸鹽、抗腫瘤鉑錯合物及免疫檢查點調節子之間的新穎組合
TWI921668B (zh) Kras g12c抑制劑之給藥方案
CN114533886B (zh) 一种用于晚期乳腺癌治疗的药物组合物
US20250019441A1 (en) Treatment of cancer with anti-ilt2 antibodies
CN120346313A (zh) 治疗肿瘤的药物组合
WO2023230554A1 (en) Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
BR122025009416A2 (pt) Combinação farmacêutica compreendendo um anticorpo anti-pd-l1 e um anticorpo anti-ctla-4, seu uso, uso de um anticorpo anti-pd-l1, uso de um anticorpo anti-ctla-4 e composição
TW202517295A (zh) 包含3,5-二取代苯炔基化合物與免疫檢查點抑制藥之癌症治療法
WO2024231875A1 (en) Hpk1 inhibitor for use in the treatment of cancer
CN120936360A (zh) 包括心脏耐受性hdac抑制剂的方法和组合物